Reboxetine augmentation of fluoxetine for patients with major depressive disorder: An 8-week open-label study

被引：0
|
作者：
Rapaport, M
Wilcox, C
Heiser, J
Londborg, P
Schwartz, G
机构：
[1] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA
[2] Pharmacol Res Inst, Los Alamitos, CA USA
[3] Summit Res Network, Seattle, WA USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2002年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S205 / S205
页数：1
相关论文
共 50 条
  • [31] Aripiprazole Plus Topiramate in Opioid-Dependent Patients With Schizoaffective Disorder: An 8-Week, Open-Label, Uncontrolled, Preliminary Study
    Bruno, Antonio
    Romeo, Vincenzo M.
    Pandolfo, Gianluca
    Scimeca, Giuseppe
    Zoccali, Rocco A.
    Muscatello, Maria Rosaria A.
    SUBSTANCE ABUSE, 2014, 35 (02) : 119 - 121
  • [32] The Efficacy and Safety of Switching to Ziprasidone from Olanzapine in Patients with Bipolar I Disorder: An 8-Week, Multicenter, Open-Label Study
    Hwang-Bin Lee
    Bo-Hyun Yoon
    Young-Joon Kwon
    Young Sup Woo
    Jung-Goo Lee
    Moon-Doo Kim
    Won-Myong Bahk
    Clinical Drug Investigation, 2013, 33 : 743 - 753
  • [33] Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study
    Boellner, Samuel W.
    Earl, Craig Q.
    Arora, Sanjay
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (12) : 2457 - 2465
  • [34] Major depressive disorder, sleep EEG and agomelatine: an open-label study
    Salva, Maria-Antonia Quera
    Vanier, Bernard
    Laredo, Judith
    Hartley, Sarah
    Chapotot, Florian
    Moulin, Catherine
    Lofaso, Frederic
    Guilleminault, Christian
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2007, 10 (05): : 691 - 696
  • [35] A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder
    El Hage, Cynthia
    Ghabrash, Maykel E.
    Dubreucq, Simon
    Brissette, Suzanne
    Lesperance, Francois
    Lesperance, Paul
    Ouellet-Plamondon, Clairelaine
    Bruneau, Julie
    Jutras-Aswad, Didier
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2018, 33 (05) : 268 - 273
  • [36] Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder
    Andersen, SW
    Clemow, DB
    Corya, SA
    JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (11) : 1468 - 1476
  • [37] Agomelatine as a Novel Treatment Option in Panic Disorder, Results From an 8-Week Open-Label Trial
    Huijbregts, Klaas M.
    Batelaan, Neeltje M.
    Schonenberg, Judy
    Veen, Gerthe
    van Balkom, Anton J.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2015, 35 (03) : 336 - 338
  • [38] Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study
    Arango, Celso
    Fegert, Joerg M.
    Picarel-Blanchot, Francoise
    Marx, Ute
    Truffaut-Chalet, Lucie
    Penelaud, Pierre-Francois
    Buitelaar, Jan
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2024,
  • [39] Efficacy of Reboxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder in Boys With Intolerance to M ethylphenidate: An Open-Label, 8-Week, Methylphenidate-Controlled Trial
    Cohen-Yavin, Iris
    Yoran-Hegesh, Roni
    Strous, Rael D.
    Kotler, Moshe
    Weizman, Abraham
    Spivak, Baruch
    CLINICAL NEUROPHARMACOLOGY, 2009, 32 (04) : 179 - 182
  • [40] Comparison of The Efficacy and Safety of Sertraline, Reboxetine, and Venlafaxine in Patients with Major Depressive Disorder: A Pooled Analysis of Four Randomized, Open-Label Trials
    Akkaya, Cengiz
    Kirli, Selcuk
    Eker, Salih Saygin
    Cangur, Sengul
    Canbazoglu, Mustafa
    Sarandol, Asli
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2010, 20 (04): : 274 - 287
12345